Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...

The jury is out on whether the artificial-intelligence trade is now a bubble. But the last few weeks have shown that high ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

DexCom delivered 22% revenue growth in the third quarter. U.S. revenue grew 21% year over year, while revenue in Dexcom's international markets rose 22%. GAAP (generally accepted accounting principles ...

Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by system complexity and sensitivity, particularly when imaging ...